CEM-directed biopsy is critical to diagnosis of lesions seen only with this modality and thus clinical implementation of CEM. We present our institutional experience from a vendor-initiated, post-FDA approval, pre-market evaluation of a CEM biopsy system (Hologic, Inc, Bedford, MA).
Learning Objectives:
Recognize that CEM-guided biopsy is an easily implemented stereotactic procedure performed in the breast imaging department
Establish that lesion enhancement during CEM-guided biopsy persists through post-procedure mammography, allowing time for technical adjustments during the procedure for optimal visualization and patient comfort
Describe that this technique using familiar stereotactic guidance principles will require very little additional training to be successfully implemented into the clinical workflow
